{"generic":"Octreotide Acetate","drugs":["Octreotide Acetate","SandoSTATIN","SandoSTATIN LAR Depot"],"mono":{"0":{"id":"419990-s-0","title":"Generic Names","mono":"Octreotide Acetate"},"1":{"id":"419990-s-1","title":"Dosing and Indications","sub":[{"id":"419990-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Acromegaly, Inadequate response to or ineligible for surgery, radiation, or bromocriptine mesylate:<\/b> initial, 50 mcg SUBQ\/IV 3 times daily (octreotide acetate injection)<\/li><li><b>Acromegaly, Inadequate response to or ineligible for surgery, radiation, or bromocriptine mesylate:<\/b> maintenance, 100-500 mcg SUBQ\/IV 3 times daily (octreotide acetate injection)<\/li><li><b>Acromegaly, Inadequate response to or ineligible for surgery, radiation, or bromocriptine mesylate:<\/b> initial (as conversion from octreotide acetate injection), 20 mg IM intragluteally at 4-week intervals for 3 months (octreotide acetate injectable suspension (Sandostatin LAR(R) Depot))<\/li><li><b>Acromegaly, Inadequate response to or ineligible for surgery, radiation, or bromocriptine mesylate:<\/b> after initial 3 months, continue 20 mg IM intragluteally every 4 weeks if GH is less than or equal to 2.5 ng\/mL, IGF-1 is normal, and clinical symptoms have improved (octreotide acetate injectable suspension (Sandostatin LAR(R) Depot))<\/li><li><b>Acromegaly, Inadequate response to or ineligible for surgery, radiation, or bromocriptine mesylate:<\/b> after initial 3 months, increase to 30 mg IM intragluteally every 4 weeks if GH is greater than 2.5 ng\/mL, IGF-1 is elevated, and\/or clinical symptoms uncontrolled (octreotide acetate injectable suspension (Sandostatin LAR(R) Depot))<\/li><li><b>Acromegaly, Inadequate response to or ineligible for surgery, radiation, or bromocriptine mesylate:<\/b> after initial 3 months, decrease to 10 mg IM intragluteally every 4 weeks if GH is less than or equal to 1 ng\/mL, IGF-I is normal, and clinical symptoms are controlled (octreotide acetate injectable suspension (Sandostatin LAR(R) Depot))<\/li><li><b>Acromegaly, Inadequate response to or ineligible for surgery, radiation, or bromocriptine mesylate:<\/b> increase dose to 40 mg IM intragluteally every 4 weeks in patients whose GH, IGF-1, and symptoms are not adequately controlled at 30 mg (octreotide acetate injectable suspension (Sandostatin LAR(R) Depot))<\/li><li><b>Carcinoid syndrome, Metastatic; symptomatic treatment:<\/b> initial, 100-600 mcg\/day SUBQ\/IV in 2-4 divided doses for 2 weeks (octreotide acetate injection)<\/li><li><b>Carcinoid syndrome, Metastatic; symptomatic treatment:<\/b> maintenance, 450 mcg\/day SUBQ\/IV (range 50-1500 mcg\/day; experience with doses above 750 mcg\/day is limited) (octreotide acetate injection)<\/li><li><b>Carcinoid syndrome, Metastatic; symptomatic treatment:<\/b> initial, 20 mg IM intragluteally at 4-week intervals for 2 months (octreotide acetate injectable suspension (Sandostatin LAR(R) Depot)); continue SUBQ octreotide acetate injections for at least 2 weeks during the switch to octreotide acetate injectable suspension<\/li><li><b>Carcinoid syndrome, Metastatic; symptomatic treatment:<\/b> after 2 months of initial therapy, increase dose to 30 mg IM intragluteally every 4 weeks if symptoms not adequately controlled (octreotide acetate injectable suspension (Sandostatin LAR(R) Depot))<\/li><li><b>Carcinoid syndrome, Metastatic; symptomatic treatment:<\/b> after 2 months of initial therapy, decrease dose to 10 mg IM intragluteally in patients who achieve good symptom control; increase dose to 20 mg IM every 4 weeks if symptoms recur (octreotide acetate injectable suspension (Sandostatin LAR(R) Depot))<\/li><li><b>Drug-induced hypoglycemia, Sulfonylurea:<\/b> 75 mcg subQ plus 50 mL of 50% dextrose IV and oral carbohydrates<\/li><li><b>Insulinoma:<\/b> Optimal dosing and timing not yet defined<\/li><li><b>Non-infective diarrhea:<\/b> Optimal dosing and timing not yet defined<\/li><li><b>Vasoactive intestinal peptide-secreting tumor, Associated diarrhea:<\/b> initial, 200 to 300 mcg\/day SUBQ\/IV in 2 to 4 divided doses for 2 weeks (range 150 to 750 mcg) (octreotide acetate injection)<\/li><li><b>Vasoactive intestinal peptide-secreting tumor, Associated diarrhea:<\/b> maintenance, adjust to achieve therapeutic response (usually not more than 450 mcg\/day SUBQ\/IV is required) (octreotide acetate injection)<\/li><li><b>Vasoactive intestinal peptide-secreting tumor, Associated diarrhea:<\/b> initial, 20 mg IM intragluteally at 4-week intervals for 2 months (octreotide acetate injectable suspension (Sandostatin LAR(R) Depot)) continue SUBQ octreotide acetate injections for at least 2 weeks during the switch to octreotide acetate injectable suspension<\/li><li><b>Vasoactive intestinal peptide-secreting tumor, Associated diarrhea:<\/b> after 2 months of initial therapy, increase dose to 30 mg IM intragluteally every 4 weeks if symptoms not adequately controlled (octreotide acetate injectable suspension (Sandostatin LAR(R) Depot))<\/li><li><b>Vasoactive intestinal peptide-secreting tumor, Associated diarrhea:<\/b> after 2 months of initial therapy, decrease dose to 10 mg IM intragluteally in patients who achieve good symptom control; increase dose to 20 mg IM every 4 weeks if symptoms recur (octreotide acetate injectable suspension (Sandostatin LAR(R) Depot))<\/li><\/ul>"},{"id":"419990-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy in children not established"},{"id":"419990-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment (adults), octreotide acetate injection:<\/b> dosage adjustments may be necessary in patients with severe renal failure requiring dialysis since the half-life of the drug can be increased<\/li><li><b>renal impairment requiring dialysis (adults), octreotide acetate suspension (Sandostatin LAR(R) Depot):<\/b> the starting dose should be 10 mg every 4 weeks<\/li><li><b>renal impairment, mild, moderate, or severe, not requiring dialysis (adults), octreotide acetate suspension (Sandostatin LAR(R) Depot):<\/b> no dose adjustment is required for the starting dose<\/li><li><b>hepatic impairment (adults; cirrhotic patients), octreotide acetate suspension (Sandostatin LAR(R) Depot):<\/b> the starting dose should be 10 mg every 4 weeks.<\/li><\/ul>"},{"id":"419990-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Acromegaly, Inadequate response to or ineligible for surgery, radiation, or bromocriptine mesylate<\/li><li>Carcinoid syndrome, Metastatic; symptomatic treatment<\/li><li>Vasoactive intestinal peptide-secreting tumor, Associated diarrhea<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>AIDS - Diarrhea<\/li><li>Bleeding esophageal varices<\/li><li>Cryptosporidiosis<\/li><li>Diabetes mellitus<\/li><li>Drug-induced hypoglycemia, Sulfonylurea<\/li><li>Dumping syndrome<\/li><li>Hypothalamic obesity<\/li><li>Insulinoma<\/li><li>Lymphorrhea<\/li><li>Necrotizing pancreatitis, acute; Adjunct<\/li><li>Neuroendocrine tumor; Adjunct<\/li><li>Non-infective diarrhea<\/li><li>Pituitary adenoma<\/li><li>Polycystic ovary syndrome<\/li><li>Polyostotic fibrous dysplasia of bone; Adjunct<\/li><li>Zollinger-Ellison syndrome; Adjunct<\/li><\/ul>"}]},"3":{"id":"419990-s-3","title":"Contraindications\/Warnings","sub":[{"id":"419990-s-3-9","title":"Contraindications","mono":"sensitivity to octreotide or any of its components <br\/>"},{"id":"419990-s-3-10","title":"Precautions","mono":"<ul><li>Cardiovascular:<\/li><li>-- ECG changes have been observed in patients with acromegaly; dosage adjustment in concurrent beta-blocker therapy may be required<\/li><li>Endocrine and Metabolic:<\/li><li>-- hyperglycemia or hypoglycemia may occur; monitoring recommended in patients with diabetes mellitus; dosage adjustment in insulin or other hypoglycemic medications may be required<\/li><li>thyroid abnormalities may occur; baseline and periodic thyroid function assessment recommended during chronic therapy<\/li><li>-- depressed vitamin B-12 levels and abnormal Schilling's tests have been reported; monitoring recommended during chronic use<\/li><li>Gastrointestinal:<\/li><li>-- biliary tract abnormalities may occur during therapy or following withdrawal<\/li><li>-- altered absorption of dietary fats may occur<\/li><li>Renal:<\/li><li>-- use caution in patients with severe renal failure requiring dialysis; maintenance dose adjustment may be required<\/li><\/ul>"},{"id":"419990-s-3-11","title":"Pregnancy Category","mono":"<ul><li>Octreotide: B (FDA)<\/li><li>Octreotide: C (AUS)<\/li><\/ul>"},{"id":"419990-s-3-12","title":"Breast Feeding","mono":"Octreotide: Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"419990-s-4","title":"Drug Interactions","sub":[{"id":"419990-s-4-13","title":"Contraindicated","mono":"<ul><li>Amifampridine (theoretical)<\/li><li>Bepridil (theoretical)<\/li><li>Cisapride (theoretical)<\/li><li>Dronedarone (theoretical)<\/li><li>Levomethadyl (theoretical)<\/li><li>Mesoridazine (established)<\/li><li>Pimozide (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Saquinavir (theoretical)<\/li><li>Sparfloxacin (theoretical)<\/li><li>Terfenadine (theoretical)<\/li><li>Thioridazine (theoretical)<\/li><li>Ziprasidone (theoretical)<\/li><\/ul>"},{"id":"419990-s-4-14","title":"Major","mono":"<ul><li>Acarbose (theoretical)<\/li><li>Acecainide (theoretical)<\/li><li>Acetophenazine (theoretical)<\/li><li>Ajmaline (theoretical)<\/li><li>Albiglutide (theoretical)<\/li><li>Alogliptin (theoretical)<\/li><li>Amiodarone (theoretical)<\/li><li>Amisulpride (theoretical)<\/li><li>Amitriptyline (theoretical)<\/li><li>Amoxapine (theoretical)<\/li><li>Anagrelide (theoretical)<\/li><li>Apomorphine (theoretical)<\/li><li>Aprindine (theoretical)<\/li><li>Aripiprazole (theoretical)<\/li><li>Arsenic Trioxide (theoretical)<\/li><li>Asenapine (theoretical)<\/li><li>Astemizole (theoretical)<\/li><li>Azimilide (theoretical)<\/li><li>Azithromycin (theoretical)<\/li><li>Bretylium (theoretical)<\/li><li>Buserelin (theoretical)<\/li><li>Canagliflozin (theoretical)<\/li><li>Chloral Hydrate (theoretical)<\/li><li>Chloroquine (theoretical)<\/li><li>Chlorpromazine (theoretical)<\/li><li>Chlorpropamide (theoretical)<\/li><li>Ciprofloxacin (theoretical)<\/li><li>Citalopram (theoretical)<\/li><li>Clarithromycin (theoretical)<\/li><li>Clomipramine (theoretical)<\/li><li>Clozapine (theoretical)<\/li><li>Crizotinib (theoretical)<\/li><li>Cyclosporine (probable)<\/li><li>Dabrafenib (theoretical)<\/li><li>Dapagliflozin (theoretical)<\/li><li>Dasatinib (theoretical)<\/li><li>Degarelix (theoretical)<\/li><li>Delamanid (theoretical)<\/li><li>Desipramine (theoretical)<\/li><li>Deslorelin (theoretical)<\/li><li>Dibenzepin (theoretical)<\/li><li>Disopyramide (theoretical)<\/li><li>Dofetilide (theoretical)<\/li><li>Dolasetron (theoretical)<\/li><li>Domperidone (theoretical)<\/li><li>Donepezil (probable)<\/li><li>Doxepin (theoretical)<\/li><li>Droperidol (theoretical)<\/li><li>Dulaglutide (theoretical)<\/li><li>Empagliflozin (theoretical)<\/li><li>Encainide (theoretical)<\/li><li>Enflurane (theoretical)<\/li><li>Erythromycin (theoretical)<\/li><li>Escitalopram (theoretical)<\/li><li>Ethopropazine (theoretical)<\/li><li>Exenatide (theoretical)<\/li><li>Fingolimod (theoretical)<\/li><li>Flecainide (theoretical)<\/li><li>Fluconazole (theoretical)<\/li><li>Fluoxetine (theoretical)<\/li><li>Fluphenazine (theoretical)<\/li><li>Foscarnet (theoretical)<\/li><li>Gatifloxacin (theoretical)<\/li><li>Gemifloxacin (probable)<\/li><li>Glimepiride (theoretical)<\/li><li>Glipizide (theoretical)<\/li><li>Glyburide (theoretical)<\/li><li>Gonadorelin (theoretical)<\/li><li>Goserelin (theoretical)<\/li><li>Granisetron (theoretical)<\/li><li>Halofantrine (theoretical)<\/li><li>Haloperidol (theoretical)<\/li><li>Halothane (theoretical)<\/li><li>Histrelin (theoretical)<\/li><li>Hydroquinidine (theoretical)<\/li><li>Hydroxychloroquine (probable)<\/li><li>Ibutilide (theoretical)<\/li><li>Iloperidone (theoretical)<\/li><li>Imipramine (theoretical)<\/li><li>Insulin (theoretical)<\/li><li>Insulin Aspart, Recombinant (theoretical)<\/li><li>Insulin Bovine (theoretical)<\/li><li>Insulin Degludec (theoretical)<\/li><li>Insulin Detemir (theoretical)<\/li><li>Insulin Glulisine (theoretical)<\/li><li>Insulin Lispro, Recombinant (theoretical)<\/li><li>Isoflurane (theoretical)<\/li><li>Isradipine (theoretical)<\/li><li>Ivabradine (theoretical)<\/li><li>Ketoconazole (theoretical)<\/li><li>Lapatinib (theoretical)<\/li><li>Leuprolide (theoretical)<\/li><li>Levofloxacin (theoretical)<\/li><li>Lidoflazine (theoretical)<\/li><li>Linagliptin (theoretical)<\/li><li>Liraglutide (theoretical)<\/li><li>Lixisenatide (theoretical)<\/li><li>Lopinavir (theoretical)<\/li><li>Lorcainide (theoretical)<\/li><li>Lumefantrine (theoretical)<\/li><li>Mefloquine (theoretical)<\/li><li>Metformin (theoretical)<\/li><li>Methadone (theoretical)<\/li><li>Methotrimeprazine (theoretical)<\/li><li>Metronidazole (theoretical)<\/li><li>Mifepristone (theoretical)<\/li><li>Miglitol (theoretical)<\/li><li>Moxifloxacin (theoretical)<\/li><li>Nafarelin (theoretical)<\/li><li>Nateglinide (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Norfloxacin (theoretical)<\/li><li>Nortriptyline (theoretical)<\/li><li>Ofloxacin (theoretical)<\/li><li>Ondansetron (theoretical)<\/li><li>Paliperidone (theoretical)<\/li><li>Panobinostat (theoretical)<\/li><li>Pasireotide (theoretical)<\/li><li>Pazopanib (theoretical)<\/li><li>Pentamidine (theoretical)<\/li><li>Perflutren Lipid Microsphere (theoretical)<\/li><li>Perphenazine (theoretical)<\/li><li>Pioglitazone (theoretical)<\/li><li>Pipotiazine (theoretical)<\/li><li>Pirmenol (theoretical)<\/li><li>Posaconazole (theoretical)<\/li><li>Prajmaline (theoretical)<\/li><li>Pramlintide (theoretical)<\/li><li>Probucol (theoretical)<\/li><li>Procainamide (theoretical)<\/li><li>Prochlorperazine (theoretical)<\/li><li>Promazine (theoretical)<\/li><li>Promethazine (theoretical)<\/li><li>Propafenone (theoretical)<\/li><li>Propiomazine (theoretical)<\/li><li>Protriptyline (theoretical)<\/li><li>Quetiapine (theoretical)<\/li><li>Quinidine (theoretical)<\/li><li>Quinine (theoretical)<\/li><li>Ranolazine (theoretical)<\/li><li>Repaglinide (theoretical)<\/li><li>Risperidone (theoretical)<\/li><li>Rosiglitazone (theoretical)<\/li><li>Salmeterol (theoretical)<\/li><li>Saxagliptin (theoretical)<\/li><li>Sematilide (theoretical)<\/li><li>Sertindole (theoretical)<\/li><li>Sevoflurane (theoretical)<\/li><li>Sitagliptin (theoretical)<\/li><li>Sodium Phosphate (theoretical)<\/li><li>Sodium Phosphate, Dibasic (theoretical)<\/li><li>Sodium Phosphate, Monobasic (theoretical)<\/li><li>Solifenacin (theoretical)<\/li><li>Sorafenib (theoretical)<\/li><li>Sotalol (theoretical)<\/li><li>Spiramycin (theoretical)<\/li><li>Sulfamethoxazole (theoretical)<\/li><li>Sultopride (theoretical)<\/li><li>Sunitinib (theoretical)<\/li><li>Tedisamil (theoretical)<\/li><li>Telavancin (theoretical)<\/li><li>Telithromycin (theoretical)<\/li><li>Tetrabenazine (theoretical)<\/li><li>Thiethylperazine (theoretical)<\/li><li>Tolazamide (theoretical)<\/li><li>Tolbutamide (theoretical)<\/li><li>Toremifene (theoretical)<\/li><li>Trazodone (theoretical)<\/li><li>Trifluoperazine (theoretical)<\/li><li>Triflupromazine (theoretical)<\/li><li>Trimeprazine (theoretical)<\/li><li>Trimethoprim (theoretical)<\/li><li>Trimipramine (theoretical)<\/li><li>Triptorelin (theoretical)<\/li><li>Vandetanib (theoretical)<\/li><li>Vardenafil (theoretical)<\/li><li>Vasopressin (theoretical)<\/li><li>Vemurafenib (theoretical)<\/li><li>Vildagliptin (theoretical)<\/li><li>Vinflunine (theoretical)<\/li><li>Voriconazole (theoretical)<\/li><li>Zolmitriptan (theoretical)<\/li><li>Zotepine (theoretical)<\/li><\/ul>"},{"id":"419990-s-4-15","title":"Moderate","mono":"<ul>Pegvisomant (established)<\/ul>"}]},"5":{"id":"419990-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Abdominal discomfort (acromegaly, 34% to 61%; other conditions, 5% to 10%), Abdominal pain (acromegaly, 25% to 28.7%; carcinoid or vasoactive intestinal peptide tumors, 10% to 35.4%), Diarrhea (acromegaly, 34% to 61%; other conditions, 5% to 10%; hypothalamic obesity (pediatric), 37%), Flatulence (up to 25.7%), Nausea (acromegaly, 10.3% to 61%; carcinoid or vasoactive intestinal peptide tumors, 24% to 40.9%; other conditions, 5% to 10%)<\/li><li><b>Musculoskeletal:<\/b>Backache (1% to 26.9%)<\/li><li><b>Neurologic:<\/b>Dizziness (5% to 20%), Headache (6% to 30%)<\/li><li><b>Other:<\/b>Fatigue (subQ, 1% to 11.5%; IM, 8% to 31.8%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Bradyarrhythmia (19% to 25%), Cardiac dysrhythmia, Congestive heart failure (less than 1%), Electrocardiogram abnormal<\/li><li><b>Endocrine metabolic:<\/b>Hyperglycemia (acromegaly, 15% to 16%; carcinoid, 27%; other conditions, 1.5%), Hypoglycemia (1.5% to 4%), Hypothyroidism (2% to 12%)<\/li><li><b>Gastrointestinal:<\/b>Ascending cholangitis<\/li><\/ul>"},"6":{"id":"419990-s-6","title":"Drug Name Info","sub":{"0":{"id":"419990-s-6-17","title":"US Trade Names","mono":"<ul><li>SandoSTATIN<\/li><li>SandoSTATIN LAR Depot<\/li><\/ul>"},"2":{"id":"419990-s-6-19","title":"Class","mono":"<ul><li>Endocrine-Metabolic Agent<\/li><li>Somatostatin (class)<\/li><\/ul>"},"3":{"id":"419990-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"419990-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"419990-s-7","title":"Mechanism Of Action","mono":"Octreotide acetate, a cyclic octapeptide agent, inhibits growth hormone, glucagon, and insulin more effectively than the natural hormone, somatostatin. Its suppression of luteinizing hormone's (LH) response to gonadotrophin releasing hormone (GnRH) and inhibition of the release of serotonin, gastrin, vasoactive intestinal peptide (VIP), secretin, motilin, and pancreatic polypeptide are similar to somatostatin's actions. The drug also reduces growth hormone and\/or IGF-I (somatomedin C) in acromegaly, inhibits gallbladder contractions, reduces bile secretion and suppresses the secretion of thyroid stimulating hormone (TSH).<br\/>"},"8":{"id":"419990-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"419990-s-8-23","title":"Absorption","mono":"<ul><li>Subcutaneous: time to peak concentration, 0.4 h<\/li><li>Subcutaneous, Acromegaly: time to peak concentration, 0.7 h<\/li><li>Bioavailability: (subcutaneous, long-acting), 60% to 63% compared to immediate-release form<\/li><\/ul>"},"1":{"id":"419990-s-8-24","title":"Distribution","mono":"<ul><li>Vd: 13.6 L<\/li><li>Vd: (Acromegaly), 21.6 L +\/- 8.5 L<\/li><li>Protein binding: about 65%<\/li><li>Protein binding: (Acromegaly), 41.2%<\/li><\/ul>"},"3":{"id":"419990-s-8-26","title":"Excretion","mono":"Renal: about 32% unchanged <br\/>"},"4":{"id":"419990-s-8-27","title":"Elimination Half Life","mono":"<ul><li>1.7 h<\/li><li>Elderly: increased by 46%<\/li><li>Mild renal impairment (creatinine clearance of 40 mL\/min to 60 mL\/min): 2.4 h<\/li><li>Moderate renal impairment (creatinine clearance of 10 mL\/min to 39 mL\/min): 3 h<\/li><li>Severe renal impairment not requiring dialysis (creatinine clearance of less than 10 mL\/min): 3.1 h<\/li><li>Severe renal failure requiring dialysis: prolonged<\/li><li>Liver cirrhosis: 3.7 h<\/li><li>Fatty liver disease: 3.4 h<\/li><\/ul>"}}},"9":{"id":"419990-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/><ul><li>octreotide acetate injection, administer SUBQ or IV<\/li><li>octreotide acetate suspension (Sandostatin LAR(R) depot), administer IM intragluteal only; never give SUBQ or IV<\/li><li>octreotide acetate suspension (Sandostatin LAR(R) depot), administer immediately (IM intragluteally) following preparation<\/li><li>rotate injection sites<\/li><\/ul><\/li><li><b>Injection, subcutaneous<\/b><br\/><ul><li>octreotide acetate injection, SUBQ route is the usual route of administration for control of symptoms<\/li><li>octreotide acetate injection, multiple SUBQ injections at the same site within short periods of time should be avoided; rotate systematically<\/li><li>octreotide acetate suspension (Sandostatin LAR(R) depot), do not administer SUBQ<\/li><\/ul><\/li><li><b>Intramuscular<\/b><br\/><ul><li>octreotide acetate suspension (Sandostatin LAR(R) depot), product kit should remain at room temperature for 30-60 min prior to suspension preparation; use diluent provided in kit, alternate gluteal injection sites, avoid deltoids injections<\/li><li>octreotide acetate suspension (Sandostatin LAR(R) depot), give immediately following preparation<\/li><\/ul><\/li><li><b>Intravenous<\/b><br\/><ul><li>octreotide acetate injection (IV push), give over 3 minutes<\/li><li>octreotide acetate injection (infusion), dilute in NS or D5W to volume of 50 to 200 mL; infuse over 15 to 30 minutes<\/li><li>octreotide acetate injection, emergency carcinoid crisis; may give rapid bolus<\/li><li>octreotide acetate injection, solution should be allowed to come to room temperature prior to administration<\/li><li>octreotide acetate suspension (Sandostatin LAR(R) depot), do not administer intravenously<\/li><\/ul><\/li><\/ul>"},"10":{"id":"419990-s-10","title":"Monitoring","mono":"<ul><li>symptomatic improvement<\/li><li>acromegaly: growth hormone levels at 1-4 hour intervals for 8-12 hours post dose, or somatomedin C (IGF-1) level 2 wk after initiation or dose change<\/li><li>carcinoid: urinary 5-hydroxyindole acetic acid (5-HIAA), plasma serotonin, plasma substance P<\/li><li>VIPoma: plasma vasoactive intestinal peptide (VIP)<\/li><li>periodic thyroid function, blood glucose, ECG<\/li><\/ul>"},"11":{"id":"419990-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/>Injection Solution: 50 MCG\/ML, 100 MCG\/ML, 200 MCG\/ML, 500 MCG\/ML, 1000 MCG\/ML<br\/><\/li><li><b>PremierPro Rx octreotide acetate<\/b><br\/>Injection Solution: 50 MCG\/ML, 100 MCG\/ML, 500 MCG\/ML<br\/><\/li><li><b>SandoSTATIN<\/b><br\/>Injection Solution: 50 MCG\/ML, 100 MCG\/ML, 200 MCG\/ML, 500 MCG\/ML, 1000 MCG\/ML<br\/><\/li><li><b>SandoSTATIN LAR Depot<\/b><br\/>Intramuscular Powder for Suspension: 10 MG, 20 MG, 30 MG<br\/><\/li><\/ul>"},"12":{"id":"419990-s-12","title":"Toxicology","sub":[{"id":"419990-s-12-31","title":"Clinical Effects","mono":"<b>OCTREOTIDE AND RELATED AGENTS<\/b><br\/>OVERDOSE: Overdose data are limited with these agents; hypoglycemia, flushing, dizziness and nausea have been reported. ADVERSE EFFECTS: Gastrointestinal adverse effects (eg; anorexia, nausea, vomiting, diarrhea and steatorrhea, constipation, abdominal discomfort, and flatulence) are the most common effects.  Gallstones, hypoglycemia and hyperglycemia, dizziness, pancreatitis, hypothyroidism, sinus bradycardia, conduction abnormalities, dysrhythmias, thrombocytopenia, and hepatitis have also been reported.<br\/>"},{"id":"419990-s-12-32","title":"Treatment","mono":"<b>OCTREOTIDE AND RELATED AGENTS <\/b><br\/><ul><li>Decontamination: Significant toxicity is not anticipated after ingestion because of limited  bioavailability.  Treatment is symptomatic and supportive.  Consider activated charcoal only after very large ingestions.<\/li><li>Hyperglycemia: If significant hyperglycemia occurs, careful blood glucose monitoring and insulin therapy might be required.<\/li><li>Hypoglycemia: Give dextrose if symptomatic or BS &lt;60 mg\/dL. Dose - Adult 50 mL of 50% dextrose IV push; Child 0.5 to 1 g\/kg (2-4 mL\/kg) of 25% dextrose IV push. Feed oral carbohydrates. If recurrent hypoglycemia develops, repeat dextrose bolus and follow with an infusion of 10% dextrose; titrate to a BS of 100 mg\/dL.<\/li><li>Bradycardia: ATROPINE: ADULT DOSE: BRADYCARDIA: 0.5 to 1 mg IV every 5 min. ASYSTOLE: 1 mg IV every 5 min.  Maximum total dose 3 mg or 0.04 mg\/kg.  Minimum single dose 0.5 mg. PEDIATRIC DOSE: 0.02 mg\/kg IV repeat every 5 min, minimum single dose 0.1 mg; maximum single dose child 0.5 mg, adolescent 1 mg; maximum total dose 1 mg child, 2 mg adolescent.<\/li><li>Monitoring of patient: Vital signs, liver enzyme levels, blood glucose level, electrolytes and fluid status, ECG, and continuous cardiac monitoring in symptomatic patients.<\/li><\/ul>"},{"id":"419990-s-12-33","title":"Range of Toxicity","mono":"<b>OCTREOTIDE AND RELATED AGENTS<\/b><br\/>A minimum toxic dose has not been established has not been established for these agents. Overdoses of octreotide up to 120,000 mcg infused over 8 hours have been well tolerated.  Octreotide doses of 2.5 mg (2500 mcg) subcutaneously have caused hypoglycemia, flushing, dizziness, and nausea.<br\/>"}]},"13":{"id":"419990-s-13","title":"Clinical Teaching","mono":"<ul><li>Drug may also cause abdominal discomfort, constipation, diarrhea, flatulence, nausea, dizziness, or headache.<\/li><li>Patient should report signs\/symptoms of hypothyroidism, pancreatitis, cardiac dysrhythmia, or bradycardia.<\/li><li>Report signs\/symptoms of cholelithiasis. which may occur during or following withdrawal of drug therapy.<\/li><li>This drug may cause hypo- or hyperglycemia. Advise patients with diabetes mellitus to monitor for and report changes in glucose control, as antidiabetic drug dosages may need to be adjusted during octreotide therapy.<\/li><li>Teach patient proper technique and placement of injections.<\/li><li>Advise patient to rotate injection sites.<\/li><li>Tell patient to call healthcare professional if a treatment is missed, as drug should be given on a regular schedule.<\/li><\/ul>"}}}